KR920007629A - SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물 - Google Patents

SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물 Download PDF

Info

Publication number
KR920007629A
KR920007629A KR1019910018639A KR910018639A KR920007629A KR 920007629 A KR920007629 A KR 920007629A KR 1019910018639 A KR1019910018639 A KR 1019910018639A KR 910018639 A KR910018639 A KR 910018639A KR 920007629 A KR920007629 A KR 920007629A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
active ingredient
acid
salt
mthf
Prior art date
Application number
KR1019910018639A
Other languages
English (en)
Other versions
KR100187992B1 (ko
Inventor
라 그레차 피에트로
Original Assignee
리비오 카모치
바이오리서치 에스. 피. 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리비오 카모치, 바이오리서치 에스. 피. 에이 filed Critical 리비오 카모치
Publication of KR920007629A publication Critical patent/KR920007629A/ko
Application granted granted Critical
Publication of KR100187992B1 publication Critical patent/KR100187992B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 AIDS환자 그룹 1에게는 MTHF 및 SAMe를 투여하고 ADIS환자 그룹 2에게는 위약만을 투여한 후 AIDS환자의 뇌척수액중 SAMe, MTHF 및 네오프테린의 처리전 농도 및 처리후 농도를 각각 도시하고
제2도는 AIDS 환자 그룹 3에게 MTHF를 투여하고 AIDS환자 그룹 4에게는 SAMe를 투여한 후 AIDS환자의 뇌척수액중 SAMe, MTHF 및 네오프테린의 처리전 농도 및 처리후 농도를 각각 도시한다.

Claims (7)

  1. 유효성분으로서 S-아데노실메티오닌의 염, 5-메틸테트라 하이드로폴산(5-MTHF)및 5-포르밀테트라 하이드로폴산(5-FTHF)또는 이의 염증에서 선택된 화합물 1개 이상을 약제학적으로 허용 가능한 부형제와 함께 함유함을 특징으로 하는, 환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물.
  2. 제1항에 있어서, 유효성분이 S-아데노실-L-메티오닌(SALMe) 및 테트라하이드로폴산의 유도체로 이루어지는 경우,S-아데노실-L-메티오닌 염과 5-메틸-테트라하이드로폴산 또는5-포르밀테트라 하이드로폴산과 중량비가 10:1 내지 4:1임을 특징으로 하는 약제학적 조성물.
  3. 제2항에 있어서, 유효성분이 S-아데노실-L-메티오닌 및 테트라하이드로폴산의 유도체로 이루어진 경우, S-아데노실-L-메니오닌 염과 5-메틸-테트라하이드로폴산 또는 5-포ㅡ밀테트라 하이드로폴산과 중량비가 8/1임을 특징으로 하는 약제학적 조성물.
  4. 제1항에 있어서, 약제학적 조성물이 유효성분을 20 내지 2,000mg의 양으로 함유함을 특징으로 하는 약제학적 조성물.
  5. 제1항에 있어서, 약량학적 단위가 S-아네노실-L-메티오닌만을 유효성분으로서 100 내지 2,000mg의 양으로 함유함을 특징으로 하는 약제학적 조성물.
  6. 제1항에 있어서, 약량학적 단위가 5-메틸네트라하이드로폴산 또는 5-포르밀테르라하이드로폴산을 유효성분으로서 20 내지 200mg의 양으로 함유함을 특징으로 하는 약제학적 조성물.
  7. 제1항에 있어서, 안정한 단일 유효성분 제형으로부터 개지되는 투여시 약제학적 조성물을 즉시 제조함을 특징으로 하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910018639A 1990-10-23 1991-10-23 S-아데노실-l-메티오닌 염, 5-메틸테트라하이드로폴산 및 5-포르밀테트라하이드로폴산으로 이루어진 그룹으로부터 선택된 하나 이상의 화합물을 활성 성분으로서 함유하는, aids환자의 신경학적 질환의 치료시 활성을 나타내는 약제학적 조성물 KR100187992B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT02183390A IT1243859B (it) 1990-10-23 1990-10-23 Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
IT21833A/90 1990-10-23

Publications (2)

Publication Number Publication Date
KR920007629A true KR920007629A (ko) 1992-05-27
KR100187992B1 KR100187992B1 (ko) 1999-06-01

Family

ID=11187495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910018639A KR100187992B1 (ko) 1990-10-23 1991-10-23 S-아데노실-l-메티오닌 염, 5-메틸테트라하이드로폴산 및 5-포르밀테트라하이드로폴산으로 이루어진 그룹으로부터 선택된 하나 이상의 화합물을 활성 성분으로서 함유하는, aids환자의 신경학적 질환의 치료시 활성을 나타내는 약제학적 조성물

Country Status (13)

Country Link
US (1) US6093703A (ko)
EP (1) EP0482493B1 (ko)
JP (1) JP3289928B2 (ko)
KR (1) KR100187992B1 (ko)
AT (1) ATE199319T1 (ko)
AU (1) AU645854B2 (ko)
CA (1) CA2053826C (ko)
DE (1) DE69132542T2 (ko)
FI (1) FI914919A (ko)
IT (1) IT1243859B (ko)
NO (1) NO914157D0 (ko)
PT (1) PT99300B (ko)
ZA (1) ZA918355B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
CN1122456C (zh) * 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
DE19628514C1 (de) * 1996-07-05 1997-09-25 E Dr Grundmann Kombination von S-Adenosylmethionin und Azidothymidin zur Hemmung der HIV-Replikation
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
US7071230B2 (en) 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US8642581B1 (en) 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US6759395B2 (en) 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
ITMI20012462A1 (it) * 2001-11-22 2003-05-22 Gnosis Srl Processo per la preparazione di compresse comprendenti s-adenosilmetionina
US20030155045A1 (en) * 2002-02-05 2003-08-21 Williams Peter C. Lubricated low temperature carburized stainless steel parts
ATE498401T1 (de) * 2004-09-15 2011-03-15 Nipro Corp Wässrige, stabile (6s)-folinsäurelösung zur injektion
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
ITMI20050485A1 (it) * 2005-03-23 2006-09-24 Truffini & Regge Farmaceutici Formulazioni granulari rivestite
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
AU2006237346B2 (en) * 2005-04-20 2011-04-07 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
EP2189154A1 (en) * 2008-11-25 2010-05-26 Gnosis S.p.A. Effervescent tablets and mouth-soluble granulates of S-adenosyl methionine and process for the preparation thereof
CN101862333B (zh) * 2009-04-20 2013-07-24 天津药物研究院 左亚叶酸钠稳定的口服制剂及其制备方法
WO2012012902A1 (en) * 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
CA3162668A1 (en) 2010-02-12 2011-08-18 Gentelon, Inc. Compositions and methods for treating depression
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
JPH04503286A (ja) * 1989-02-09 1992-06-11 バートン・ジェフリー・ジェームズ ステレオシステムのための信号増補プロセッサ
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE4005275A1 (de) * 1990-02-20 1991-08-22 Grundmann Ewald Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren

Also Published As

Publication number Publication date
ATE199319T1 (de) 2001-03-15
NO914157D0 (no) 1991-10-23
CA2053826C (en) 2002-12-17
DE69132542T2 (de) 2001-06-21
DE69132542D1 (de) 2001-04-05
JP3289928B2 (ja) 2002-06-10
PT99300A (pt) 1992-08-31
FI914919A (fi) 1992-04-24
EP0482493A3 (en) 1992-09-02
AU645854B2 (en) 1994-01-27
CA2053826A1 (en) 1992-04-24
IT9021833A0 (it) 1990-10-23
ZA918355B (en) 1992-07-29
EP0482493B1 (en) 2001-02-28
AU8670891A (en) 1992-04-30
KR100187992B1 (ko) 1999-06-01
IT1243859B (it) 1994-06-28
IT9021833A1 (it) 1992-04-23
JPH04264031A (ja) 1992-09-18
PT99300B (pt) 1999-04-30
FI914919A0 (fi) 1991-10-18
US6093703A (en) 2000-07-25
EP0482493A2 (en) 1992-04-29

Similar Documents

Publication Publication Date Title
KR920007629A (ko) SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR910019618A (ko) 발기부전증 치료용 제약 조성물
DK0538011T3 (da) Saltsammensætninger omfattende lipofilt oligosaccharidantibiotikum.
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
ATE173627T1 (de) Medizinische zusammensetzung
FI940696A (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
KR970025615A (ko) 암 전이 억제제
KR880007073A (ko) 의 약 품
DE69222698D1 (de) 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze
KR880007060A (ko) 제약 조성물
FR2674754B1 (fr) Composition medicamenteuse micronisee.
KR900013969A (ko) 지루를 감소시키는 약학 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, s-아데노실메티오닌 및 이들의 염의 용도 및 이와 관련된 약학 조성물
KR920000326A (ko) 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
KR890007740A (ko) 제약학적 조성물
PT99091A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da triazina e da pirimidina, como ingredientes activos, destinadas a reverter a resistencia aos agentes anticancerosos e antimalaricos
KR930001906A (ko) 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
TH41946A (th) นิวคลีโอไซด์ที่ใช้ในการรักษาโรค
KR870000071A (ko) 수의 운동을 개선하는 신규약제 조성물 및 그의 생산공정
KR900700086A (ko) 뇌기능 개선약
KR920016091A (ko) 완전 비경구 영양법에 의해 유발되는 간내 담즙분비정지의 치료에 있어서 s-아데노실-l-메티오닌의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030108

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee